Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e32-e34. doi: 10.1111/jdv.19408. Epub 2023 Aug 23.

Elisabeth Cohen^{1

2}, Alizée Bozonnat^{1

3}, Maxime Battistella^{3

4

5}, Julien Calvani^{3

4

5}, Marie-Dominique Vignon-Pennamen⁴, Jacqueline Rivet⁴, Hélène Moins-Teisserenc^{2

3

6}, Van-Anh Ta², Caroline Ram-Wolff¹, Jean-David Bouaziz^{1

3

5}, Thibault Mahevas¹, Martine Bagot^{1

3

5}, Samia Mourah^{3

5

7}, Baptiste Louveau^{3

5

7}, Flore Sicre de Fontbrune⁸, Regis Peffault de Latour⁸, Adèle de Masson^{1

3

5}, Gilles Battesti^{1

3}

¹ Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.
² INSERM U1160, Institut de Recherche Saint-Louis, Paris, France.
³ Université Paris Cité, Paris, France.
⁴ Department of Pathology, APHP, Saint-Louis Hospital, Paris, France.
⁵ INSERM U976, Institut de Recherche Saint-Louis, Paris, France.
⁶ Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France.
⁷ Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France.
⁸ Department of Hematology and Bone Marrow Transplant, APHP, Saint-Louis Hospital, Paris, France.

No abstract available

Publication types